Henry Ford Cancer Institute
Detroit, Michigan 48202-2610
12 studies enrolling now · 30 studies all time
What they study most
ALK-positive Non-small Cell Lung Cancer (NSCLC), AML, AML With Mutated NPM1, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia, Advanced Non-Small-Cell Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors
Studies at this site
- A Study of DM005 in Patients With Advanced Solid Tumors — Recruiting now
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Recruiting now
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) — Recruiting now
- Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT — Recruiting now
- A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
- Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer — Recruiting now
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors — Recruiting now
- A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) — Recruiting now
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) — Recruiting now
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors — Recruiting now
- Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
- A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies — Running, not enrolling
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Running, not enrolling
- A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy — Running, not enrolling
- Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer — Running, not enrolling
- A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies — Completed
- Study of Oral MRT-2359 in Selected Cancer Patients — Running, not enrolling
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage — Stopped early
- NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy — Running, not enrolling
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Running, not enrolling
- SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) — Completed
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies — Completed
- Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors — Stopped early
- Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma — Stopped early
- Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions — Stopped early
- Study of LM-102 in Subjects in Advanced Tumors — Stopped early
- KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC — Stopped early